Certolizumab pegol
- Generic Name
- Certolizumab pegol
- Brand Names
- Cimzia
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 428863-50-7
- Unique Ingredient Identifier
- UMD07X179E
- Background
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cyt...
- Indication
Certolizumab pegol has been approved for several different conditions listed below:
...
- Associated Conditions
- Moderate to Severe Plaque Psoriasis, Moderately to Severely Active Rheumatoid Arthritis, Non-radiographic Axial Spondyloarthritis, Psoriatic Arthritis, Severe Crohn's Disease, Active Ankylosing spondylitis, Active Psoriatic arthritis, Moderate Crohn’s Disease, Moderate Psoriatic Arthritis, Moderate Rheumatoid arthritis, Severe Psoriatic Arthritis, Severe Rheumatoid arthritis
- Associated Therapies
- -
A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2017-02-13
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- UCB Biopharma S.P.R.L.
- Target Recruit Count
- 127
- Registration Number
- NCT03051217
- Locations
- 🇯🇵
Ps0017 009, Minatoku, Japan
🇯🇵Ps0017 041, Matsumoto, Japan
🇯🇵Ps0017 027, Sendai, Japan
A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU
- Conditions
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 89
- Registration Number
- NCT03020992
- Locations
- 🇵🇱
As0007 509, Poznań, Poland
🇨🇿As0007 103, Brno, Czechia
🇩🇪As0007 302, München, Germany
Does Clinical Response Correlate With Serum Certolizumab Levels?
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2015-11-05
- Lead Sponsor
- Shafran Gastroenterology Center
- Target Recruit Count
- 20
- Registration Number
- NCT02597829
- Locations
- 🇺🇸
Shafran Gastroenterology Center, Winter Park, Florida, United States
An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044
- First Posted Date
- 2014-12-18
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 347
- Registration Number
- NCT02319642
- Locations
- 🇨🇳
013, Beijing, China
🇨🇳025, Beijing, China
🇨🇳021, Beijing, China
RICE: Remission by Intra-articular Injection Plus CErtolizumab
- First Posted Date
- 2014-11-18
- Last Posted Date
- 2018-08-03
- Lead Sponsor
- Rüdiger B. Müller
- Target Recruit Count
- 43
- Registration Number
- NCT02293590
- Locations
- 🇨🇭
Kantonsspital St. Gallen, St. Gallen, Saint Gallen, Switzerland
Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 156
- Registration Number
- NCT01864265
- Locations
- 🇩🇪
University of Erlangen-Nuremberg, Department of Internal Medicine 3, Rheumatology & Immunology, Erlangen, Germany
🇩🇪Medizinische Universitätsklinik Freiburg Abteilung Rheumatologie und Klinische Immunologie, Freiburg, Germany
🇩🇪Universitätsklinikum Leipzig AÖR Department Innere Medizin Sektion Rheumatologie, Leipzig, Germany
SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.
- Conditions
- Interventions
- First Posted Date
- 2011-02-14
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Julia Brown
- Target Recruit Count
- 122
- Registration Number
- NCT01295151
- Locations
- 🇬🇧
Institute of Rheumatic & Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, West Yorkshire, United Kingdom
The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients
- First Posted Date
- 2010-10-01
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- Oklahoma Medical Research Foundation
- Target Recruit Count
- 20
- Registration Number
- NCT01213017
- Locations
- 🇺🇸
Arthritis and Rheumatic Disease Specialties, Aventura, Florida, United States
🇺🇸Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States
Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2022-06-10
- Lead Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT01197066
Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol
- First Posted Date
- 2010-08-27
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 16
- Registration Number
- NCT01190410
- Locations
- 🇺🇸
126, Morristown, New Jersey, United States
🇺🇸104, Baltimore, Maryland, United States
🇺🇸114, Orange, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.